PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2

PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2

Annual-Meeting

1 year
69 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Scott Z. Fields, MD, Bayer Pharmaceuticals explains PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2 at Annual Meeting 2018
Up Next Autoplay